Medical test maker Sequenom struggled to reassure Wall Street about the future of its Down syndrome blood test Thursday, as the company’s stock plunged 75 percent after Sequenom said employees mishandled study data and results. The news called into question…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook

Read more:
Sequenom aims to calm Wall Street as shares plunge